Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets gain on pharma, banks
Wed, 1 Apr 03:30 pm

Indian markets extended their gains over the second half of the trading session as BSE Sensex gained over 240 points and NSE-Nifty gained over 70 points. During the early trade, markets were suppressed by the fact that core sector growth declined to 1.4%. BSE Mid Cap and BSE Small Cap stocks outperformed the market as midcap companies gained nearly 1% while smallcap gained about 2%. Among the sectoral indices, IT is the only sector trading in the red with losses of about 1.3%. Today's gains are primarily attributable to banks and healthcare sector.

Commodities continue to trade in a flattish tone between small gains and losses. Gold prices, per 10 grams, declined 0.13% or Rs 34 while silver prices, per kilogram, declined 0.12% or Rs 44. While the gold prices are available at Rs 26,170 levels, silver prices are available at Rs 37,125 levels. Crude oil prices extended their sell-off to 2%. Per barrel, the crude oil declined about Rs 60 to Rs 2,965. Crude oil prices fell as nuclear talks with Iran extended beyond the pre-decided deadline. The US dollar against the Indian Rupee remains unchanged at Rs 62.4950.

Metals stocks are trading with moderate gains as stocks gained about 0.4% in today's trading session. However, shares of Tata Steel gained about 0.5% in today's trading session as it divested its 100% Sri Lankan based subsidiary named Lanka Special Steels Limited for a consideration of Rs 200 m. The company had an annual turnover of Rs 740 m. The facility had an installed capacity of 14,400 mta. Business of the company included supplying and manufacturing hot dip galvanized wire and nail.

Pharmaceutical has led today's gains with over 1%. Apart from Dr. Reddy's, Sun Pharma has gained above 4% in today's trade. Shares of Dr. Reddy's gained over 2% after the company revealed that it would be acquiring a selected portfolio of UCB that includes India, Sri Lanka, Maldivies and Nepal. The acquisition is valued to be Rs 8 billion. The selected portfolio of UCB will be sold on a "slump sale basis". It also has about 350 employees working in the company. This acquisition will help Dr. Reddy's leverage its footprint on a global basis and will also help it expand its portfolio of products in the therapeutic areas of dermatology, respiratory and pediatrics among others.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets gain on pharma, banks". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.